Ocular Therapeutix Inc. (OCUL)

4.14
0.13 3.04
NASDAQ : Health Technology
Prev Close 4.27
Open 4.26
Day Low/High 4.14 / 4.42
52 Wk Low/High 2.35 / 7.31
Volume 696.91K
Avg Volume 735.70K
Exchange NASDAQ
Shares Outstanding 47.20M
Market Cap 202.94M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Ocular Therapeutix™ To Report Third Quarter 2017 Financial Results

Ocular Therapeutix™ To Report Third Quarter 2017 Financial Results

Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that...

Ocular Therapeutix is Now Oversold (OCUL)

Ocular Therapeutix is Now Oversold (OCUL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Robbins Arroyo LLP Is Investigating The Officers And Directors Of Ocular Therapeutix, Inc. (OCUL) On Behalf Of Shareholders

Robbins Arroyo LLP Is Investigating The Officers And Directors Of Ocular Therapeutix, Inc. (OCUL) On Behalf Of Shareholders

Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Ocular Therapeutix, Inc.

Ocular Therapeutix™ Appoints Donald Notman As Chief Financial Officer

Ocular Therapeutix™ Appoints Donald Notman As Chief Financial Officer

Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced the...

Notable Monday Option Activity: OCUL, COHU, HUM

Notable Monday Option Activity: OCUL, COHU, HUM

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Ocular Therapeutix Inc , where a total volume of 1,623 contracts has been traded thus far today, a contract volume which is representative of approximately 162,300 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 52% of OCUL's average daily trading volume over the past month, of 312,065 shares.

Ocular Therapeutix™ Appoints Michael Goldstein, M.D., M.B.A., As Chief Medical Officer

Ocular Therapeutix™ Appoints Michael Goldstein, M.D., M.B.A., As Chief Medical Officer

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced the...

Ocular Therapeutix™ To Present At Three Upcoming Investor Conferences

Ocular Therapeutix™ To Present At Three Upcoming Investor Conferences

Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that...

OCULAR THERAPEUTIX INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ocular Therapeutix, Inc. To Contact The Firm

OCULAR THERAPEUTIX INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ocular Therapeutix, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Ocular Therapeutix, Inc.

OCULAR THERAPEUTIX ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ocular Therapeutix, Inc. To Contact The Firm

OCULAR THERAPEUTIX ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ocular Therapeutix, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Ocular Therapeutix, Inc.

Ocular Therapeutix™ Reports Second Quarter 2017 Financial Results And Provides Corporate Update

Ocular Therapeutix™ Reports Second Quarter 2017 Financial Results And Provides Corporate Update

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Ocular Therapeutix, Inc. Of Class Action Lawsuit And Upcoming Deadline - OCUL

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Ocular Therapeutix, Inc. Of Class Action Lawsuit And Upcoming Deadline - OCUL

Pomerantz LLP announces that a class action lawsuit has been filed against Ocular Therapeutix, Inc.

Ocular Therapeutix™ Appoints Daniel Bollag, Ph.D., As Senior Vice President, Regulatory Affairs, Pharmacovigilance And Quality

Ocular Therapeutix™ Appoints Daniel Bollag, Ph.D., As Senior Vice President, Regulatory Affairs, Pharmacovigilance And Quality

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced the...

RSI Alert: Ocular Therapeutix (OCUL) Now Oversold

RSI Alert: Ocular Therapeutix (OCUL) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ocular Therapeutix™ Announces Antony Mattessich Assumes Role As Chief Executive Officer

Ocular Therapeutix™ Announces Antony Mattessich Assumes Role As Chief Executive Officer

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced...

Ocular Therapeutix™ To Report Second Quarter 2017 Financial Results

Ocular Therapeutix™ To Report Second Quarter 2017 Financial Results

Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that...

OCUL LOSS NOTICE: Rosen Law Firm Reminds Ocular Therapeutix, Inc. Investors Of Important Deadline In First Filed Class Action - OCUL

OCUL LOSS NOTICE: Rosen Law Firm Reminds Ocular Therapeutix, Inc. Investors Of Important Deadline In First Filed Class Action - OCUL

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Ocular Therapeutix, Inc.

The Klein Law Firm Reminds Investors Of A Class Action Filed On Behalf Of Ocular Therapeutix, Inc. Shareholders And A Lead Plaintiff Deadline Of September 5, 2017

The Klein Law Firm Reminds Investors Of A Class Action Filed On Behalf Of Ocular Therapeutix, Inc. Shareholders And A Lead Plaintiff Deadline Of September 5, 2017

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ocular Therapeutix, Inc.

The Klein Law Firm Announces A Class Action Filed On Behalf Of Ocular Therapeutix, Inc. Shareholders And A Lead Plaintiff Deadline Of September 5, 2017

The Klein Law Firm Announces A Class Action Filed On Behalf Of Ocular Therapeutix, Inc. Shareholders And A Lead Plaintiff Deadline Of September 5, 2017

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ocular Therapeutix, Inc.

First Week of March 2018 Options Trading For Ocular Therapeutix (OCUL)

First Week of March 2018 Options Trading For Ocular Therapeutix (OCUL)

Investors in Ocular Therapeutix Inc saw new options become available this week, for the March 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Ocular Therapeutix, Inc. (OCUL)

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Ocular Therapeutix, Inc. (OCUL)

The Klein Law Firm announces the commencement of an investigation of Ocular Therapeutix, Inc.

OCUL INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Ocular Therapeutix, Inc. And A Lead Plaintiff Deadline Of September 5, 2017

OCUL INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Ocular Therapeutix, Inc. And A Lead Plaintiff Deadline Of September 5, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Ocular Therapeutix, Inc.

OCUL SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of Commencement Of A Class Action Involving Ocular Therapeutix, Inc. And A Lead Plaintiff Deadline Of September 5, 2017

OCUL SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of Commencement Of A Class Action Involving Ocular Therapeutix, Inc. And A Lead Plaintiff Deadline Of September 5, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Ocular Therapeutix, Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Ocular Therapeutix, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 5, 2017

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Ocular Therapeutix, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 5, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Ocular Therapeutix, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Ocular Therapeutix, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 5, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Ocular Therapeutix, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 5, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Ocular Therapeutix, Inc.

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Ocular Therapeutix, Inc.

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Ocular Therapeutix, Inc.

The Klein Law Firm announces the commencement of an investigation of Ocular Therapeutix, Inc.

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Ocular Therapeutix, Inc.

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Ocular Therapeutix, Inc.

The Klein Law Firm announces the commencement of an investigation of Ocular Therapeutix, Inc.

EQUITY ALERT UPDATE: Rosen Law Firm Expands First Filed Securities Class Action Against Ocular Therapeutix, Inc. To Include Investors Who Purchased Up To July 11, 2017

EQUITY ALERT UPDATE: Rosen Law Firm Expands First Filed Securities Class Action Against Ocular Therapeutix, Inc. To Include Investors Who Purchased Up To July 11, 2017

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of Ocular Therapeutix, Inc.

OCUL INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Ocular Therapeutix, Inc.

OCUL INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Ocular Therapeutix, Inc.

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Ocular Therapeutix, Inc.

OCUL SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Ocular Therapeutix, Inc.

OCUL SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Ocular Therapeutix, Inc.

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Ocular Therapeutix, Inc.

TheStreet Quant Rating: D- (Sell)